FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:1528-1529 December 1, 1994 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

To the Editor: Doxorubicin is a widely used and effective antineoplastic agent. However, doxorubicin therapy is limited by dose-dependent cardiotoxicity that may lead to congestive heart failure.¹ To optimize doxorubicin therapy, it is important to detect early signs of cardiac toxicity. To measure the severity of myocardial damage and dysfunction, cardiac catheterization and endomyocardial biopsy have been used, as have electrocardiography, echocardiography, and radionuclear angiography. However, these methods all have limitations, are inadequate for the serial monitoring of individual patients, or both.

Levels of endothelin-1 peptide are transiently increased after physical stress.^2,3 While studying sequential changes in plasma endothelin-1 levels . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Daugaard, G., Lassen, U., Bie, P., Pedersen, E. B., Jensen, K. T., Abildgaard, U., Hesse, B., Kjaer, A. (2005). Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 7: 87-93 [Abstract] [Full Text]  
• Gharib, M.I., Burnett, A.K. (2002). Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 4: 235-242 [Abstract] [Full Text]